Evidence map›Paper›PMID 35992570›Full record

ArticleAdvances in radiation oncology

COVID-19 vaccine-induced Recurrence of the Radiation Recall Phenomenon in the Laryngeal Mucosa Due to a VEGF Inhibitor.

Shotaro Tatekawa, Shigenori Hoshino, Norihiko Takemoto, Michio Oda, Yuichi Akino, Kota Iwahori, Takero Hirata, Kazuhiko Hayashi, Keisuke Tamari, Yuji Seo and 3 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Shotaro TatekawaDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Shigenori HoshinoDepartment of Respiratory Medicine, Saito Yukoukai Hospital, Osaka, Japan.
Norihiko TakemotoDepartment of Otorhinolaryngology, Saito Yukoukai Hospital, Osaka, Japan.
Michio OdaDepartment of Medical Technology, Osaka University Hospital, Osaka, Japan.
Yuichi AkinoDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kota IwahoriDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
Takero HirataDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kazuhiko HayashiDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Keisuke TamariDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Yuji SeoDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Fumiaki IsohashiDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Shinichi ShimizuDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kazuhiko OgawaDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
The University of Osaka · JPOsaka University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The radiation recall phenomenon (RRP) is a rare and unexpected late complication of radiation therapy (RT). Although predominantly in the skin, RRP of the upper respiratory tract has also been reported. In general, RRP is caused by anticancer agents, and the COVID-19 vaccine has also been reported to cause RRP in recent years. Methods and Materials: A 50-year-old woman who had received RT around the larynx 3 years prior and was receiving a docetaxel + ramucirumab (RAM) regimen experienced recurrent sore throat. The administration of RAM was discontinued after a gastroscopic examination revealed mucosal bleeding from around the larynx, which was thought to be RRP caused by RAM, a vascular endothelial growth factor inhibitor. Results: After the remission of the RRP, the patient received a COVID-19 vaccine (Pfizer-BioNTech). Five days later, the appearance of cough and recurrence of sore throat worsened with time, and marked stridor was observed. The patient was admitted, and steroid pulse therapy was administered for 3 days starting on day 18 after vaccination. On day 50 after vaccination, edema of the vocal cords improved. Conclusions: When administering COVID-19 vaccines, considering that these vaccines may cause RRP is important, because RRP can be fatal in patients with a history of RT in the laryngeal region and treated with vascular endothelial growth factor inhibitors.

Identifiers

PMID35992570
PMCPMC9376028
OpenAlexW4291335318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.